Evidence map›Paper›PMID 38279325›Full record

ArticleInternational journal of molecular sciences2024

The Influence of HLA Polymorphisms on the Severity of COVID-19 in the Romanian Population.

Mihaela Laura Vică, Minodora Dobreanu, Ghenadie Curocichin, Horea Vladi Matei, Ștefana Bâlici, Mihaela Elvira Vușcan, Alin Dan Chiorean, Gheorghe Zsolt Nicula, Daniela Cristina Pavel Mironescu, Daniel Corneliu Leucuța and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Mihaela Laura VicăDepartment of Cell and Molecular Biology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.ORCID 0000-0003-0811-0821
Minodora DobreanuEmergency Clinical County Hospital, 540136 Târgu Mureș, Romania.ORCID 0000-0003-3214-3631
Ghenadie CurocichinDepartment of Family Medicine, "Nicolae Testemițanu" State University of Medicine and Pharmacy, MD-2004 Chișinău, Moldova.
Horea Vladi MateiDepartment of Cell and Molecular Biology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
Ștefana BâliciDepartment of Cell and Molecular Biology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
Mihaela Elvira VușcanDepartment of Cell and Molecular Biology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
Alin Dan ChioreanDepartment of Cell and Molecular Biology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
Gheorghe Zsolt NiculaDepartment of Cell and Molecular Biology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
Daniela Cristina Pavel MironescuDepartment of Cell and Molecular Biology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
Daniel Corneliu LeucuțaDepartment of Medical Informatics and Biostatistics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.ORCID 0000-0003-4218-8622
Cosmin Adrian TeodoruClinical Surgical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania.
Costel Vasile SisermanLegal Medicine Institute, 400006 Cluj-Napoca, Romania.
Iuliu Hațieganu University of Medicine and Pharmacy · ROLucian Blaga University of Sibiu · RONicolae Testemițanu State University of Medicine and Pharmacy · MDUniversitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș · RO

Funding

Agence Universitaire de la Francophonie DRECO-6775
6 · The paper itself

Abstract

In this study, we aimed to investigate whether specific HLA alleles found in patients from Romania and the Republic of Moldova were associated with the severity of COVID-19 infection and its associated mortality. We analyzed the HLA alleles at the -A, -B, -C, -DRB1, and -DQB1 loci in a cohort of 130 individuals with severe and extremely severe forms of COVID-19, including 44 individuals who died. We compared these findings to a control group consisting of individuals who had either not been diagnosed with COVID-19 or had experienced mild forms of the disease. Using multivariate logistic regression models, we discovered that the B*27 and B*50 alleles were associated with an increased susceptibility to developing a severe form of COVID-19. The A*33 and C*15 alleles showed potential for offering protection against the disease. Furthermore, we identified two protective alleles (A*03 and DQB1*02) against the development of extremely severe forms of COVID-19. By utilizing score statistics, we established a statistically significant association between haplotypes and disease severity (

Indexed as

COVID-19Genetic Predisposition to DiseaseAllelesGene FrequencyGenotypeHaplotypesHLA-DRB1 ChainsHumansRomaniaHLA-DRB1 ChainsCOVID-19HLAMHCRepublic of MoldovaRomaniaSARS-CoV-2

Identifiers

PMID38279325
PMCPMC10816224
OpenAlexW4391106254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.